Article ID Journal Published Year Pages File Type
8453402 Leukemia Research 2018 6 Pages PDF
Abstract
In this retrospective analysis, RA and RARS/RARS-t patients receiving ICT had superior OS to non-ICT patients. These findings should be verified and other MDS subtypes examined in larger prospective analyses.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Authors
, ,